论文部分内容阅读
本科从1996年3月至1997年5月对估计化疗后会出现严重骨髓抑制的“高危”患者化疗后48小时起应用Gran能防治化疗后中性粒细胞减少症，150μg／天较75μg／天疗效更好，而且并不增加Gran的副作用和患者的总费用。
From March 1996 to May 1997, we evaluated the use of Gran to prevent and treat post-chemotherapy neutropenia at “high risk”, estimated to be severe myelosuppression 48 hours after chemotherapy in patients with chemotherapy-induced neutropenia at 150 μg / day vs 75 μg / day The effect is better, and does not increase Gran’s side effects and the total cost of the patient.